

A **once-daily pill** for moderate to severe ulcerative colitis (UC)

Take as directed by your doctor if certain liver problems exist.

OLD ME
thought some
UC relief was the
best I could do

**MEET THE
ZEPOSIA
ME**



ZEPOSIA[®]
(ozanimod) | 0.92 mg capsules



37% achieved remission at 1 year vs 19% on placebo.

ZEPOSIA[®] (ozanimod) is a prescription medicine used to treat moderately to severely active ulcerative colitis (UC) in adults.

It is not known if ZEPOSIA is safe and effective in children.

SELECTED IMPORTANT SAFETY INFORMATION

Do not take ZEPOSIA if you:

- have had a heart attack, chest pain (unstable angina), stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure in the last 6 months

This list (“Do not take ZEPOSIA if you:”) continues inside.



Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

What can once-daily ZEPOSIA offer?

Take as directed by your doctor if certain liver problems exist.



Lasting remission (fewer symptoms and reduced inflammation seen during a colonoscopy at 1 year).*

*37% achieved remission vs 19% on placebo. Reduces symptoms of rectal bleeding and stool frequency. Reduced inflammation representing mild or inactive disease in the colon.



An advanced, once-daily pill that offers **UC relief without having to take steroids**† And you don't have to try injections or infusions (biologics) first.

†Advanced therapies=S1P receptor modulators, biologics, and JAK inhibitors. 32% of patients achieved steroid-free remission at 1 year vs 17% on placebo.



Provides help with **intestinal healing by visibly reducing inflammation** on and below the surface of the colon lining.‡

‡30% of patients achieved this result at 1 year compared to 14% on placebo. Impact of intestinal healing on UC progression and long-term outcomes was not studied.



Reduced rectal bleeding and fewer trips to the bathroom in **as early as 2 weeks**.

Learn more about the ZEPOSIA® (ozanimod) clinical studies on [page 4](#).

SELECTED IMPORTANT SAFETY INFORMATION

Do not take ZEPOSIA if you (cont'd):

- have or have had a history of certain types of an irregular or abnormal heartbeat (arrhythmia) that is not corrected by a pacemaker
- have untreated, severe breathing problems during your sleep (sleep apnea)
- take certain medicines called monoamine oxidase (MAO) inhibitors (such as selegiline, phenelzine, linezolid)

Talk to your healthcare provider before taking ZEPOSIA if you have any of these conditions or do not know if you have any of these conditions.

What's inside

WHY ZEPOSIA	3
Clinical study results	4
How ZEPOSIA works	6
Safety and side effects	8
Taking ZEPOSIA.....	9
Getting started	9
ZEPOSIA SUPPORT	10
Talking to your doctor.....	13

You can find all of this information and more at ZEPOSIA.com/UC




Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

A once-daily pill for UC

Take as directed by your doctor if certain liver problems exist.

In this section, you'll find helpful information about ZEPOSIA® (ozanimod), including:

- **Study results**
- **How ZEPOSIA works**
- **Safety and side effects**
- **Information about taking ZEPOSIA**



Actual Size

— Height: 0.56 inches
Width: 0.21 inches

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including:

- **Infections.** ZEPOSIA can increase your risk of serious infections that can be life-threatening and cause death. ZEPOSIA lowers the number of white blood cells (lymphocytes) in your blood. This will usually go back to normal within 3 months of stopping treatment. Your healthcare provider may do a blood test of your white blood cells before you start taking ZEPOSIA.

Continue reading for additional serious side effects on [page 4](#).

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).



More is possible— with proven results

Symptom improvement and lasting remission

AT 2 WEEKS



You can experience **early symptom relief with reduced rectal bleeding and fewer trips to the bathroom.**

AT 10 WEEKS



48% of patients experienced symptom improvement and 18% were in remission.*

AT 1 YEAR



60% of patients experienced symptom improvement and 37% were in remission.†

*26% of patients taking placebo achieved symptom improvement and 6% achieved remission.

†41% of patients taking placebo achieved symptom improvement and 19% achieved remission.

Individual results may vary.

More than half the people in remission at 10 weeks with ZEPOSIA® (ozanimod) continued to experience lasting remission at the **1-year mark (n = 41/79).**

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

How the study was designed

ZEPOSIA was studied in a 1-year clinical study where all participants (ZEPOSIA: 429, placebo: 216) were evaluated at 10 weeks. Those who had achieved symptom improvement at 10 weeks were then able to continue (ZEPOSIA: 230, placebo: 227) and be evaluated at 1 year. Patients were to be receiving treatment with an oral 5-ASA and/or steroids to enter the study.

To learn more about the **ZEPOSIA clinical trials**, visit ZEPOSIA.com/UCresults

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including (cont'd):

Call your healthcare provider right away if you have any of these symptoms of an infection during treatment with ZEPOSIA and for 3 months after your last dose of ZEPOSIA:

- fever
- feeling very tired
- flu-like symptoms
- cough
- painful and frequent urination (signs of a urinary tract infection)
- rash
- headache with fever, neck stiffness, sensitivity to light, nausea, or confusion (these may be symptoms of meningitis, an infection of the lining around your brain and spine)

Your healthcare provider may delay starting or may stop your ZEPOSIA treatment if you have an infection.

Keep reading to see more information about how symptom improvement and remission were defined.



More about clinical trials

How was symptom improvement defined?

Symptom improvement, or “clinical response,” was defined as an improvement in symptoms (stool frequency and rectal bleeding) and/or the clinical results of a colonoscopy. This can be different for everyone because it is based on the severity of your UC when you start treatment.

How was remission defined?

- No rectal bleeding
- Reduction of stool frequency to normal, or 1 or 2 stools more than normal
- Improvement in how the intestinal lining looked during a colonoscopy, representing mild or inactive disease in the colon



Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

Reduced intestinal inflammation



ZEPOSIA® (ozanimod) can help with intestinal healing by visibly reducing inflammation on and below the surface of the colon lining.*

*30% of patients achieved this result at 1 year compared to 14% on placebo. Impact of intestinal healing on UC progression and long-term outcomes was not studied.

Steroid-free remission



You can **experience lasting steroid-free remission** with ZEPOSIA.†

†32% of patients achieved steroid-free remission at 1 year vs 17% on placebo. Individual results may vary.

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including (cont'd):

- **Progressive multifocal leukoencephalopathy (PML).** ZEPOSIA can increase your risk for PML, which is a rare brain infection that usually leads to death or severe disability. If PML happens, it usually happens in people with weakened immune systems but has happened in people who do not have weakened immune systems. Symptoms of PML get worse over days to weeks. Call your doctor right away if you have any new or worsening symptoms of PML that have lasted several days, including: weakness on one (1) side of your body, changes in your vision, changes in your thinking or memory, confusion, changes in your personality, loss of coordination in your arms or legs, decreased strength, and/or problems with balance.



How ZEPOSIA is thought to treat UC



ZEPOSIA® (ozanimod) is the **first treatment of its kind approved for ulcerative colitis (UC)** that targets a specific part of immune cells called an S1P receptor. The S1P receptor plays a role in the UC inflammation process.

SELECTED IMPORTANT SAFETY INFORMATION

ZEPOSIA may cause serious side effects, including (cont'd):

- **Slow heart rate (also known as bradyarrhythmia) when you start taking ZEPOSIA.** ZEPOSIA may cause your heart rate to temporarily slow down, especially during the first 8 days. You will have a test to check the electrical activity of your heart called an electrocardiogram (ECG) before you take your first dose of ZEPOSIA.

Call your healthcare provider if you experience the following symptoms of slow heart rate:

- dizziness
- lightheadedness
- feeling like your heart is beating slowly or skipping beats
- shortness of breath
- confusion
- chest pain
- tiredness

Follow directions from your healthcare provider when starting ZEPOSIA and when you miss a dose. Continue reading for additional possible serious side effects of ZEPOSIA.

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

About the immune system

The immune system is the body's natural defense against infection. Immune cells circulate in the bloodstream, some of them passing through small glands called lymph nodes, where they are directed to wherever they are needed.

If a problem is detected, like an infection, immune cells circulating in the body recruit more cells from the lymph nodes to help fight it off.




ZEPOSIA
(ozanimod) | 0.92 mg capsules



What happens in people with UC

The exact cause of ulcerative colitis (UC) is unknown, but it is believed to be related to an irregular immune response. In UC, the immune system **responds incorrectly** and recruits immune cells to the colon (large intestines and rectum). This results in **ongoing (chronic) inflammation** that damages the colon and causes the symptoms that people with UC may experience.



SELECTED IMPORTANT SAFETY INFORMATION

Before taking ZEPOSIA® (ozanimod), tell your healthcare provider about all of your medical conditions, including if you:


- have a fever or infection, or are unable to fight infections due to a disease, or take or have taken medicines that lower your immune system
- received a vaccine in the past 30 days or are scheduled to receive a vaccine. ZEPOSIA may cause vaccines to be less effective
- before you start ZEPOSIA, your healthcare provider may give you a chickenpox (Varicella Zoster Virus) vaccine if you have not had one before

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

How ZEPOSIA is thought to work

The exact way ZEPOSIA works is not fully understood.

- ZEPOSIA attaches to a part of the immune cell called S1P receptors
- This helps prevent these immune cells from leaving the lymph nodes and entering the colon
- By keeping these cells out of the intestines, ZEPOSIA may help prevent them from causing some of the damaging inflammation seen in UC



To learn more about **how ZEPOSIA is meant to work** for UC, visit ZEPOSIA.com/treatingUC



A well-established safety profile

The safety of ZEPOSIA® (ozanimod) has been studied across:

- **4 clinical studies**
- **2 conditions**—ulcerative colitis (UC) and multiple sclerosis
- **Over 1,300 patients**

At 10 weeks of treatment, 94% of patients remained on ZEPOSIA in the UC clinical studies, and 3.3% stopped due to a side effect they experienced (N=429).

At 1 year of treatment, 80% of patients remained on ZEPOSIA and 1.3% stopped due to a side effect they experienced (N=230).

Possible serious side effects

ZEPOSIA may cause serious side effects, including:

- Infections
- Progressive multifocal leukoencephalopathy (PML)
- Slow heart rate (bradyarrhythmia)
- Liver problems
- Increased blood pressure
- Breathing problems, such as shortness of breath
- Macular edema (a vision problem)
- Swelling and narrowing of blood vessels in your brain

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

Most common side effects

During the clinical study, people who took ZEPOSIA were asked to report side effects they experienced. These were the most common:

- Upper respiratory tract infections
- Elevated liver enzymes
- Low blood pressure when you stand up (orthostatic hypotension)
- Painful and frequent urination (signs of urinary tract infection)
- Back pain
- High blood pressure
- Headache

These are not all the possible side effects of ZEPOSIA. Please see the [Prescribing Information](#) for information on all of the side effects reported by those taking ZEPOSIA. If you experience any side effects while taking ZEPOSIA, be sure to talk to your healthcare provider right away.

How many patients have received ZEPOSIA?

Since it was first approved, approximately **35,000 patients** have received ZEPOSIA across two conditions.*

*As of April 30, 2023.

For more information about **how many people experienced common side effects**, visit ZEPOSIA.com/safety



Taking ZEPOSIA

ZEPOSIA® (ozanimod) is a **pill, taken once a day** as close to the same time as possible. If you have certain liver problems, take ZEPOSIA as directed by your healthcare provider. It can be taken:



- **With or without food**
- **When and where you want**—ZEPOSIA has no requirement for refrigeration

SELECTED IMPORTANT SAFETY INFORMATION

Before taking ZEPOSIA, tell your healthcare provider about all of your medical conditions, including if you (cont'd):

- have had chickenpox or have received the vaccine for chickenpox. Your healthcare provider may do a blood test for the chickenpox virus. You may need to get the full course of the vaccine and wait 1 month before taking ZEPOSIA
- have a slow heart rate
- have an irregular or abnormal heartbeat (arrhythmia)
- have a history of stroke
- have or have had heart problems, including a heart attack or chest pain
- have high blood pressure
- have liver problems
- have breathing problems, including during your sleep
- have eye problems, especially an inflammation of the eye called uveitis
- have diabetes

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

A gradual start designed with you in mind

If you and your healthcare provider decide to move forward with ZEPOSIA, there may be some initial routine tests required before starting.

Learn more by clicking the link below.

Once you've been approved to begin treatment, you'll receive the ZEPOSIA Starter Kit. It will either be provided to you by your healthcare team or delivered directly to your home. Please see additional eligibility requirements on [page 16](#).



The ZEPOSIA Starter Kit includes your first 28 doses and has two parts:

- 1. A 7-day Starter Pack** for your first week of treatment. The pills in this pack help increase your dosage of ZEPOSIA gradually. Each pill is labeled with the day and dosage. Be sure to follow the instructions written on the pack and take the pills in the correct order.
- 2. The regular dosage of ZEPOSIA** (orange capsules) you'll begin taking on day 8 (after completing the 7-day Starter Pack).

To learn more about **getting started on ZEPOSIA**, visit ZEPOSIA.com/start





Supporting you every step of the way

ZEPOSIA 360 Support™ has materials and resources designed to help you get the support you need, whether you're considering ZEPOSIA® (ozanimod) or already getting started with treatment.

Through ZEPOSIA 360 Support communications, you will receive:

- Assistance in exploring available support and savings options
- Help navigating your insurance benefits*
- Support if you are having problems with insurance approvals
- Important program updates
- Helpful alerts sent right to your phone (optional)

To learn more about **the ZEPOSIA 360 Support program**, visit ZEPOSIA.com/supportprogram



*The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. Bristol Myers Squibb and its agents make no guarantee regarding reimbursement for any service or item.

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

Support for patients taking ZEPOSIA

Connect with a Support Coordinator

If you have been prescribed ZEPOSIA® (ozanimod) and would like help answering questions about your insurance coverage and other possible access support options, your Support Coordinator can help.



Contact ZEPOSIA 360 Support™ at
1-833-ZEPOSIA (833-937-6742),
Monday to Friday, 8 AM – 8 PM ET.

Waiting on insurance?

If you have private or commercial insurance and are experiencing delays or issues with coverage, **the ZEPOSIA Bridge Program may be able to provide ZEPOSIA to you, as needed (for up to 24 months)*.**

*The Bridge Program is available at no cost for eligible, commercially insured, on-label diagnosed patients if there is a delay in determining whether commercial prescription coverage is available, and is not contingent on any purchase requirement, for up to 24 months (dispensed in 30-day increments). The Bridge Program is not available to patients who have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs and is available for no more than 12 months to patients in MA, MN, and RI. Appeal of any prior authorization denial must be made within 90 days or as per payer guidelines, to remain in the program. Eligibility will be re-verified in January for patients continuing into the following year, and may be at other times during program participation. Offer is not health insurance. Once coverage is approved by the patient's commercial insurance plan, the patient will no longer be eligible. Void where prohibited by law, taxed, or restricted. Bristol-Myers Squibb Company reserves the right to rescind, revoke, or amend this program at any time without notice. Other limitations may apply.

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

Ways to save on treatment costs

Finding financial assistance



Eligible, commercially insured patients may pay **as little as \$0 a month for ZEPOSIA.†**

Sign up for the co-pay offer at ZEPOSIA.com/360support

If you have difficulty affording medication, a Support Coordinator can help you understand your options.

†ZEPOSIA Prescription Co-pay Card Program is valid only for patients with commercial insurance. The Program includes a prescription benefit offer for out-of-pocket drug costs where the full cost of the ZEPOSIA prescription is not covered by patient's insurance. Patients are not eligible for the Program if they have prescription insurance coverage through a state or federal healthcare program, including but not limited to Medicare, Medicaid, Medigap, CHAMPUS, TRICARE, Veterans Affairs (VA), or Department of Defense (DoD) programs. Patients who move from commercial plans to state or federal healthcare programs will no longer be eligible. Patient must be 18 years of age or older. Eligible patients with an activated co-pay card and a valid prescription may pay as little as \$0 per 30-day supply; monthly, annual, and/or per-claim maximum program benefits may apply and vary from patient to patient, depending on the terms of a patient's prescription drug plan and to ensure that the funds are used for the benefit of the patient, based on factors determined solely by Bristol-Myers Squibb. Some prescription drug plans have established programs referred to as "co-pay maximizer" programs. A co-pay maximizer program is one in which the amount of the patient's out-of-pocket costs is adjusted to reflect the availability of support offered by a co-pay support program. Patients enrolled in co-pay maximizer programs may receive program benefits that vary over time to ensure the program funds are used for the benefit of the patient. The Program expires on December 31, 2023. All Program payments are for the benefit of the patient only. Patients, pharmacists, and prescribers may not seek reimbursement from health insurance, health savings or flexible spending accounts, or any third party, for any part of the prescription benefit received by the patient through this Program. Patient's acceptance of any Program benefit confirms that it is consistent with patient's insurance and that patient will report the value received as may be required by his/her insurance provider. Program valid only in the United States and Puerto Rico. Void where prohibited by law, taxed, or restricted. The Program cannot be combined with any other offer, rebate, coupon, or free trial. The Program is not conditioned on any past, present or future purchase, including refills. The Program is not insurance. Other limitations may apply. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this Program at any time without notice.



Stay informed

By clicking the link to the right, you can get access to resources and information to help you at any stage of your treatment journey.

Sign up for:

- **Information** about ZEPOSIA® (ozanimod)
- **Tips** for staying on treatment
- **Ways to live a healthy lifestyle** that can have an impact on ulcerative colitis (UC)
- **Links to helpful resources**
- **A brochure for starting ZEPOSIA** mailed directly to you
- **Helpful alerts** sent to your phone (optional)



Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).

Want to learn more?

If you're wondering if ZEPOSIA may be right for you, sign up to receive more information in the way that works best for you.

To sign up for **ZEPOSIA 360 Support™**, visit ZEPOSIA.com/360support

SELECTED IMPORTANT SAFETY INFORMATION

Before taking ZEPOSIA, tell your healthcare provider about all of your medical conditions, including if you (cont'd):

- are or plan to become pregnant or if you become pregnant within 3 months after you stop taking ZEPOSIA. ZEPOSIA may harm your unborn baby. If you are a female who can become pregnant, talk to your healthcare provider about what birth control method is right for you during your treatment with ZEPOSIA and for 3 months after you stop taking ZEPOSIA
- are breastfeeding or plan to breastfeed. It is not known if ZEPOSIA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take ZEPOSIA




Start the conversation

Still experiencing UC symptoms?

If ulcerative colitis (UC) symptoms are still getting in the way, it might be time to talk to your doctor about your treatment plan. Visit the website below to create a personalized guide to help your healthcare provider better understand your symptoms, their impact, and how to address them.

Visit ZEPOSIA.com/guide to get your personalized guide.



6 questions to ask about treatment

Being prepared with questions for your doctor can help keep the conversation focused—and allow you to get the answers you need. To learn more about ZEPOSIA® (ozanimod), here are some questions you might consider asking:

1. What impact could ZEPOSIA have on my UC?
2. How is ZEPOSIA taken, and how often?
3. How does ZEPOSIA work?
4. How does ZEPOSIA differ from other treatments I've tried for UC?
5. What are the most common side effects of ZEPOSIA?
6. Is ZEPOSIA a good fit for me?

To watch **real UC patients and their doctors** discuss their experiences with ZEPOSIA, visit ZEPOSIA.com/conversations

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).



INDICATIONS

Multiple Sclerosis (MS): ZEPOSIA® (ozanimod) is a prescription medicine used to treat relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

Ulcerative Colitis (UC): ZEPOSIA is a prescription medicine used to treat moderately to severely active ulcerative colitis (UC) in adults.

It is not known if ZEPOSIA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

Do not take ZEPOSIA if you:

- have had a heart attack, chest pain (unstable angina), stroke or mini-stroke (transient ischemic attack or TIA), or certain types of heart failure in the last 6 months
- have or have had a history of certain types of an irregular or abnormal heartbeat (arrhythmia) that is not corrected by a pacemaker
- have untreated, severe breathing problems during your sleep (sleep apnea)
- take certain medicines called monoamine oxidase (MAO) inhibitors (such as selegiline, phenelzine, linezolid)

Talk to your healthcare provider before taking ZEPOSIA if you have any of these conditions or do not know if you have any of these conditions.

ZEPOSIA may cause serious side effects, including:

- **Infections.** ZEPOSIA can increase your risk of serious infections that can be life-threatening and cause death. ZEPOSIA lowers the number of white blood cells (lymphocytes) in your blood. This will usually go back to normal within 3 months of stopping treatment. Your healthcare provider may do a blood test of your white blood cells before you start taking ZEPOSIA.

Call your healthcare provider right away if you have any of these symptoms of an infection during treatment with ZEPOSIA and for 3 months after your last dose of ZEPOSIA:

- fever
- rash
- feeling very tired

- flu-like symptoms
- cough
- painful and frequent urination (signs of a urinary tract infection)
- headache with fever, neck stiffness, sensitivity to light, nausea, or confusion (these may be symptoms of meningitis, an infection of the lining around your brain and spine)

Your healthcare provider may delay starting or may stop your ZEPOSIA treatment if you have an infection.

- **Progressive multifocal leukoencephalopathy (PML).** ZEPOSIA can increase your risk for PML, which is a rare brain infection that usually leads to death or severe disability. If PML happens, it usually happens in people with weakened immune systems but has happened in people who do not have weakened immune systems. Symptoms of PML get worse over days to weeks. Call your doctor right away if you have any new or worsening symptoms of PML that have lasted several days, including: weakness on one (1) side of your body, changes in your vision, changes in your thinking or memory, confusion, changes in your personality, loss of coordination in your arms or legs, decreased strength, and/or problems with balance.
- **Slow heart rate (also known as bradyarrhythmia) when you start taking ZEPOSIA.** ZEPOSIA may cause your heart rate to temporarily slow down, especially during the first 8 days. You will have a test to check the electrical activity of your heart called an electrocardiogram (ECG) before you take your first dose of ZEPOSIA. Call your healthcare provider if you experience the following symptoms of slow heart rate:
 - dizziness
 - lightheadedness
 - feeling like your heart is beating slowly or skipping beats
 - shortness of breath
 - confusion
 - chest pain
 - tiredness

Follow directions from your healthcare provider when starting ZEPOSIA and when you miss a dose.

Continue reading for additional possible serious side effects of ZEPOSIA.

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).



IMPORTANT SAFETY INFORMATION (cont'd)

Before taking ZEPOSIA, tell your healthcare provider about all of your medical conditions, including if you:

- have a fever or infection, or are unable to fight infections due to a disease, or take or have taken medicines that lower your immune system
- received a vaccine in the past 30 days or are scheduled to receive a vaccine. ZEPOSIA may cause vaccines to be less effective
- before you start ZEPOSIA, your healthcare provider may give you a chickenpox (Varicella Zoster Virus) vaccine if you have not had one before
- have had chickenpox or have received the vaccine for chickenpox. Your healthcare provider may do a blood test for the chickenpox virus. You may need to get the full course of the vaccine and wait 1 month before taking ZEPOSIA
- have a slow heart rate
- have an irregular or abnormal heartbeat (arrhythmia)
- have a history of stroke
- have or have had heart problems, including a heart attack or chest pain
- have high blood pressure
- have liver problems
- have breathing problems, including during your sleep
- have eye problems, especially an inflammation of the eye called uveitis
- have diabetes
- are or plan to become pregnant or if you become pregnant within 3 months after you stop taking ZEPOSIA. ZEPOSIA may harm your unborn baby. If you are a female who can become pregnant, talk to your healthcare provider about what birth control method is right for you during your treatment with ZEPOSIA and for 3 months after you stop taking ZEPOSIA. If you become pregnant while taking ZEPOSIA for MS, tell your healthcare provider right away and enroll in the ZEPOSIA Pregnancy Registry by calling 1-877-301-9314 or visiting www.zeposiapregnancyregistry.com

- are breastfeeding or plan to breastfeed. It is not known if ZEPOSIA passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take ZEPOSIA

Tell your healthcare provider about all the medicines you take or have recently taken, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Using ZEPOSIA with other medicines can cause serious side effects. Especially tell your healthcare provider if you take or have taken:

- medicines that affect your immune system, such as alemtuzumab
- medicines to control your heart rhythm (antiarrhythmics), or heartbeat
- CYP2C8 inducers such as rifampin
- CYP2C8 inhibitors such as gemfibrozil (medicine to treat high fat in your blood)
- opioids (pain medicine), medicines to treat depression, and medicines to treat Parkinson's disease
- medicines to control your heart rate and blood pressure (beta blocker medicines and calcium channel blocker medicines)

You should not receive **live** vaccines during treatment with ZEPOSIA, for at least 1 month before taking ZEPOSIA and for 3 months after you stop taking ZEPOSIA. Vaccines may not work as well when given during treatment with ZEPOSIA.

ZEPOSIA can cause serious side effects, including:

- **liver problems.** Your healthcare provider will do blood tests to check your liver before you start taking ZEPOSIA. Call your healthcare provider right away if you have any of the following symptoms:
 - unexplained nausea
 - vomiting
 - stomach area (abdominal) pain
 - tiredness
 - loss of appetite
 - yellowing of the whites of your eyes or skin
 - dark colored urine

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).



IMPORTANT SAFETY INFORMATION (cont'd)

ZEPOSIA can cause serious side effects, including (cont'd):

- **increased blood pressure.** Your healthcare provider should check your blood pressure during treatment with ZEPOSIA. A sudden, severe increase in blood pressure (hypertensive crisis) can happen when you eat certain foods that contain high levels of tyramine.
- **breathing problems.** Some people who take ZEPOSIA have shortness of breath. Call your healthcare provider right away if you have new or worsening breathing problems.
- **a problem with your vision called macular edema.** Your risk of macular edema is higher if you have diabetes or have had an inflammation of your eye called uveitis. Your healthcare provider should test your vision before you start taking ZEPOSIA if you are at higher risk for macular edema or any time you notice vision changes during treatment with ZEPOSIA. Call your healthcare provider right away if you have any of the following symptoms:
 - blurriness or shadows in the center of your vision
 - sensitivity to light
 - a blind spot in the center of your vision
 - unusually colored vision
- **swelling and narrowing of the blood vessels in your brain.** Posterior Reversible Encephalopathy Syndrome (PRES) is a rare condition that has happened with ZEPOSIA and with drugs in the same class. Symptoms of PRES usually get better when you stop taking ZEPOSIA. If left untreated, it may lead to stroke. Your healthcare provider will do a test if you have any symptoms of PRES. Call your healthcare provider right away if you have any of the following symptoms:
 - sudden severe headache
 - sudden confusion
 - sudden loss of vision or other changes in your vision
 - seizure

- **severe worsening of multiple sclerosis (MS) after stopping ZEPOSIA.** When ZEPOSIA is stopped, symptoms of MS may return and become worse compared to before or during treatment. Always talk to your healthcare provider before you stop taking ZEPOSIA for any reason. Tell your healthcare provider if you have worsening symptoms of MS after stopping ZEPOSIA.

The most common side effects of ZEPOSIA can include:

- upper respiratory tract infections
- elevated liver enzymes
- low blood pressure when you stand up (orthostatic hypotension)
- painful and frequent urination (signs of urinary tract infection)
- back pain
- high blood pressure
- headache

These are not all of the possible side effects of ZEPOSIA. For more information, ask your healthcare provider or pharmacist.

Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full [Prescribing Information](#) and [Medication Guide](#).

ZEPOSIA free trial offer

Patient must have a valid prescription for ZEPOSIA for an FDA-approved indication. Patient must be new to therapy and have not previously received a sample or filled a prescription for ZEPOSIA. Patient is responsible for applicable taxes, if any. This offer is limited to one use per patient per lifetime and is non-transferable. Cannot be combined with any other rebate/coupon, free trial, or similar offer. No substitutions permitted. Patients, pharmacists, and prescribers cannot seek reimbursement for the ZEPOSIA Free Trial from health insurance or any third party, including state or federally funded programs. Patients may not count the ZEPOSIA Free Trial as an expense incurred for purposes of determining out-of-pocket costs for any plan, including Medicare Part D true out-of-pocket costs (TrOOP). Offer is not conditioned on any past, present, or future purchase, including refills. Only valid in the United States and US Territories. Void where prohibited by law or restricted. The program is not insurance. Bristol Myers Squibb reserves the right to rescind, revoke, or amend this offer at any time without notice.

Please see Important Safety Information throughout this brochure and full [Prescribing Information](#), including [Medication Guide](#).



Inside: 6 questions to help guide a conversation with your healthcare provider



Ready to get started?

Take a look at the steps to starting ZEPOSIA® (ozanimod) at [ZEPOSIA.com/start](https://www.zeposia.com/start)



ZEPOSIA, ZEPOSIA 360 Support, and ZEPOSIA logo are trademarks of Celgene Corporation, a Bristol Myers Squibb company.

© 2023 Bristol-Myers Squibb Company. 2084-US-2300723 08/23